Merck KGaA draws the curtain on newest lipid nanoparticle for mRNA vaccines, turbocharging its annual capacity

With the miracle of mRNA vaccines turning the tide on the pandemic, the spotlight has shifted to tiny engineered fat bubbles, dubbed lipid nanoparticles, that shuttle those drugs into patients’ immune cells. Germany’s Merck KGaA, looking to corner demand for the much-in-need delivery tool is now rolling out a higher-efficiency version months ahead of schedule.